| 词条 | Grifols |
| 释义 |
| name = Grifols, S.A. | logo = Grifols.svg | logo_size = 230px | type = Sociedad Anónima | traded_as = {{ubl |{{BMAD|ES0171996012|GRF}} |{{NASDAQ|GRFS}} }} | key_people = Víctor Grífols (Chairman and CEO) | industry = Pharmaceuticals, chemicals | products = Plasma derivatives, in vitro diagnostic products, non-biological products for laboratories and hospitals | revenue = {{ubl|{{Increase}} €3,934.6 million (2015) |€3,355.4 million (2014) [1]{{rp|8}} }} | operating_income = {{ubl |{{Increase}} €970.4 million (2015) |€857.7 million (2014) [1]{{rp|8}} }} | net_income = {{ubl | {{Increase}} €532.1 million (2015) |€470.3 million (2014)[1]{{rp|8}} }} | assets = {{ubl |{{Increase}} €9,601.7 million (2015) |€8,449.7 million (2014)[1]{{rp|6}} }} | equity = {{ubl |{{Increase}} €3,301.4 million (2015) |€2,662.9 million (2014)[1]{{rp|7}} }} | num_employees = {{ubl |{{increase}} 13,731 (2015, average) |12,938 (2014, average)[1]{{rp|64}} }} | homepage = www.grifols.com | foundation = 1940 | location = Barcelona, Spain }} Grifols, S.A. ({{IPA-ca|ˈɡɾifuls|lang}}) is a Spanish multinational pharmaceutical and chemical manufacturer. Principally a producer of blood plasma-based products, a field in which it is the European leader and largest worldwide,[2][3] the company also supplies devices, instruments, and reagents for clinical testing laboratories. Main productsGrifols is the major world supplier of IVIG, albumin, Factor VIII and other plasma-derived products. Main operationsIn 2007 the company had 3.6 million litres per year of blood fractionation capacity from three plants, one at Parets del Vallès near Barcelona in Spain (2.1 million litres per year), another in Los Angeles (1.5 million litres but being expanded to 2.2 million litres), and a site in Clayton, NC. In the United States the company owns 153 plasmapheresis centres, where it collects around 5.8 million litres of plasma per year. OwnershipGrifols was listed on the Madrid Stock Exchange in May 2006.[4] The stock became part of the IBEX 35 index in January 2008. HistoryGrifols' origin lies in the laboratory founded in 1940 in Barcelona by Dr José A. Grifols Roig, a hematologist and scientist. His son, Dr José A. Grífols Lucas was the first researcher to publish the plasmapheresis procedure in 1952.[5] The company introduced its liquid IVIG product into the European market in the mid-1990s. Probitas Pharma, S.A. was incorporated with high limited liability under Spanish law on 22 June 1987; on 27 June 2005 the company changed its name to Grifols, S.A.[6] In 2003 the company acquired certain assets of the Los Angeles-based Alpha Therapeutic (US subsidiary of Mitsubishi Pharma) as the basis of its American expansion.[7] On May 17, 2006, Grifols securities were listed on Spain’s Mercado Continuo.[8] In 2009, CSL Limited attempted to takeover Talecris Biotherapeutics (the former plasma business of Bayer HealthCare LLC, Biological Products Division)[9] for $3,1 billion but was stopped by the Federal Trade Commission.[10] On June 1, 2011, a year after announcing the $4 billion deal, Grifols completed a takeover of Talecris Biotherapeutics, headquartered in Research Triangle Park in North Carolina, with over 2000 employees.[11] Grifols acquired the blood transfusion diagnostics unit from Novartis in 2013 as a "platform for global expansion".[3] This unit is based in Emeryville, California and was a part of Chiron acquired by Novartis in 2006.[3] In 2015, the company acquired a 45% stake in Alkahest as part of planned co-development of "plasma-based products for the treatment of cognitive decline in aging and disorders of the CNS, including Alzheimer's."[12] In December 2016, Grifols acquired Hologics interest in their existing joint blood screening unit for $1.85 billion[13] References1. ^1 2 3 4 5 {{cite web |url=http://www.grifols.com/documents/10192/11739017/cons-2015-en/87fb01a2-55ec-4b45-b4d0-0fe04b5cafa2 |title=Group annual consolidated accounts, auditors' report and directors' report for the financial year 2015 |accessdate=2016-06-10 |publisher=Grifols }}{{self-published inline |certain=yes |date=June 2016 }} 2. ^{{cite news|url=https://www.bloomberg.com/apps/news?pid=conewsstory&refer=conews&tkr=UBS:SM&sid=aQHCdaY7uiDg |title=Santander, Sabadell, Sol Melia, Urbas: Iberia Preview |last=Smyth |first=Sharon |date=23 June 2008 |work=Bloomberg |first2=Gareth |archive-url=https://web.archive.org/web/20121023191904/http://www.bloomberg.com/apps/news?pid=conewsstory&refer=conews&tkr=UBS%3ASM&sid=aQHCdaY7uiDg |archive-date=23 October 2012 |author2=Gore |accessdate=2009-01-18 |deadurl=yes |df= }} 3. ^1 2 {{Cite news|url=http://www.genengnews.com/gen-news-highlights/novartis-sells-blood-transfusion-dx-unit-to-grifols-for-1-675b/81249099/|title=Novartis Sells Blood Transfusion Dx Unit to Grifols|last=Staff|date=December 2013|work=Genetic Engineering & Biotechnology News|issue=21|volume=33|page=10|type=Paper}} 4. ^{{cite news|url=https://www.reuters.com/article/health-SP/idUSL1933932620070119|title=Blood firm Grifols sees 2006 sales up 22 pct|last=Dowsett|first=Sonya|date=19 January 2007|work=Reuters|accessdate=2009-01-18}} 5. ^{{cite journal|title=Use of plasmapheresis in blood donors|pmid=14916171|year=1952|last1=Grífols-Lucas|first1=JA|volume=1|issue=4763|pages=854|journal=British Medical Journal}} 6. ^{{cite web |url=https://www.grifols.com/documents/10192/30799/3_Annual_audited_accounts_2005_en/6f1da1e3-2013-4d7d-9d6e-cc94cc0c5e9a |title=Grifols S.A. (formerly Probitas Pharma S.A.) And Subsidiaries: Consolidated Annual Accounts prepared in accordance with International Financial Reporting Standards as adopted for use in the European Union and Consolidated Directors' Report |date=31 December 2005 |accessdate=2016-02-03}}{{self-published inline| certain=yes |date=June 2016 }} 7. ^{{cite press release |url=http://www.mt-pharma.co.jp/shared/show.php?url=../e/release/nr/mpc/2003/e030410.html |title=Mitsubishi Pharma to Withdraw from US Plasma Fractionation Business as US Subsidiary Transfers Operations |date=10 April 2003 |accessdate=2016-02-03 |publisher=Mitsubishi Pharma Corporation }} 8. ^{{cite news|url=http://www.efinancialnews.com/story/2006-05-01/news-in-brief-third-time-lucky-for-grifols|title=News in brief: Third time lucky for Grifols|last=Staff|date=1 May 2006|work=Financial News|location=London|accessdate=2016-02-03}} 9. ^{{cite press release |url=http://www.businesswire.com/news/home/20050401005264/en/Announcing-Launch-Talecris-Biotherapeutics-Combining-Proud-History |title=Announcing the Launch of Talecris Biotherapeutics |date=1 April 2005 |accessdate=2016-02-03 |publisher=Talecris |via=BusinessWire }} 10. ^{{cite news|url=https://www.ftc.gov/news-events/press-releases/2009/05/ftc-authorizes-suit-stop-csls-proposed-31-billion-acquisition|title=FTC Authorizes Suit To Stop CSLs Proposed $3.1 Billion Acquisition of Talecris Biotherapeutics|date=2009-05-27|accessdate=2016-02-03}} 11. ^{{cite news|url=http://www.newsobserver.com/2011/06/02/1242024/spanish-buyer-set-to-take-over.html|title=Spanish buyer set to take over Talecris|last=Wolf|first=Alan M.|work=News & Observer|date=2011-06-02|accessdate=2011-06-02|deadurl=yes|archiveurl=https://web.archive.org/web/20110605150021/http://www.newsobserver.com/2011/06/02/1242024/spanish-buyer-set-to-take-over.html|archivedate=2011-06-05|df=}} 12. ^{{Cite journal|last=Staff|date=1 April 2015|title=Grifols Makes $37.5M Investment in Alkahest|url=http://www.genengnews.com/gen-news-highlights/grifols-makes-37-5m-investment-in-alkahest/81250991/|department=News: Industry Watch|journal=Genetic Engineering & Biotechnology News|type=Paper|volume=35|issue=7|page=10}} 13. ^http://www.genengnews.com/gen-news-highlights/grifols-buys-hologics-share-in-blood-screening-unit-for-185b/81253559 Further reading
External links{{Commons category|Grifols}}{{Portal|Companies}}
8 : Companies listed on NASDAQ|Pharmaceutical companies of Spain|Pharmaceutical companies established in 1940|Companies based in Barcelona|IBEX-35|1940 establishments in Spain|Companies listed on the Madrid Stock Exchange|Spanish brands |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。